Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Open Label Study of CRISPR-CAR Genome Edited T Cells (PBLTT52CAR19) in Relapsed /Refractory B Cell Acute Lymphoblastic Leukaemia

NCT04557436 is registered in ClinicalTrials.gov with Great Ormond Street Hospital for Children NHS Foundation Trust as lead sponsor.

NCT NCT04557436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04557436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Open Label Study of CRISPR-CAR Genome Edited T Cells (PBLTT52CAR19) in Relapsed /Refractory B Cell Acute Lymphoblastic Leukaemia
Lead sponsor
Great Ormond Street Hospital for Children NHS Foundation Trust
Phase
Phase 1
Overall status
Completed
Start date
August 12, 2020
Completion date
March 5, 2024
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b acute lymphoblastic leukemia